{"slideshow_credits": null, "snippet": "Stents and sutures are not an obvious fit, Jeffrey Goldfarb and Robert Cyran of Reuters Breakingviews write, and the savings and benefits from such a merger do not appear to justify a premium of nearly $10 billion.", "abstract": "Stents and sutures are not an obvious fit, Jeffrey Goldfarb and Robert Cyran of Reuters Breakingviews write, and the savings and benefits from such a merger do not appear to justify a premium of nearly $10 billion.", "section_name": "Business Day", "print_page": null, "document_type": "blogpost", "byline": {"person": [{"firstname": "Jeffrey", "role": "reported", "lastname": "GOLDFARB", "rank": 1, "organization": ""}, {"firstname": "Robert", "role": "reported", "lastname": "CYRAN", "rank": 2, "organization": ""}], "original": "By JEFFREY GOLDFARB and ROBERT CYRAN"}, "web_url": "http://dealbook.nytimes.com/2014/06/16/medtronic-covidien-deal-is-a-marriage-of-convenience/", "lead_paragraph": null, "headline": {"main": "Medtronic-Covidien Deal Is a Marriage of Convenience", "kicker": "DealBook"}, "_id": "539f134a38f0d87596d2698c", "word_count": "400", "multimedia": [], "pub_date": "2014-06-16T11:53:11Z", "source": "The New York Times", "news_desk": "Business", "keywords": [{"name": "organizations", "value": "AstraZeneca PLC", "rank": "1"}, {"name": "organizations", "value": "Covidien plc", "rank": "2"}, {"name": "organizations", "value": "Medtronic Inc", "rank": "3"}, {"name": "organizations", "value": "Pfizer Inc", "rank": "4"}, {"name": "subject", "value": "Mergers, Acquisitions and Divestitures", "rank": "3"}, {"name": "subject", "value": "Medical Devices", "rank": "2"}, {"name": "subject", "value": "Corporate Taxes", "rank": "1"}], "blog": [], "subsection_name": "Dealbook", "type_of_material": "Blog"}